COL6A1/2/3 Antibody (172C2): sc-47764

COL6A1/2/3 Antibody (172C2) is a mouse monoclonal IgG1 kappa light chain antibody that detects COL6A1/2/3 protein of human origin by western blotting (WB), immunoprecipitation (IP), and immunofluorescence (IF). Anti-COL6A1/2/3 antibody (172C2) is available as a non-conjugated format. COL6A1/2/3 (172C2) antibody recognizes a crucial component of collagen type VI, which plays a significant role in the structural integrity and function of various connective tissues. COL6A1/2/3 is primarily located in the extracellular matrix, where COL6A1/2/3 contributes to the formation of a supportive framework for cells and tissues. Collagen type VI maintains tissue elasticity and resilience, particularly in structures such as tendons, skin, and cartilage. Collagen type VI also interacts with other extracellular matrix proteins, including fibronectin and laminin, which are vital for cell adhesion and signaling. These interactions are important for normal tissue development and repair, highlighting COL6A1/2/3′s significance in both physiological and pathological processes. Anti-COL6A1/2/3 antibody (172C2) effectively detects COL6A1/2/3, making this antibody a valuable tool for researchers studying connective tissue disorders and related conditions.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

COL6A1/2/3 Antibody (172C2) References:

1. Position of glycine substitutions in the triple helix of COL6A1, COL6A2, and COL6A3 is correlated with severity and mode of inheritance in collagen VI myopathies.  |  Butterfield, RJ., et al. 2013. Hum Mutat. 34: 1558-67. PMID: 24038877
2. H3K27 acetylation activated-COL6A1 promotes osteosarcoma lung metastasis by repressing STAT1 and activating pulmonary cancer-associated fibroblasts.  |  Zhang, Y., et al. 2021. Theranostics. 11: 1473-1492. PMID: 33391546
3. Role of COL6A2 in malignant progression and temozolomide resistance of glioma.  |  Hong, X., et al. 2023. Cell Signal. 102: 110560. PMID: 36521657
4. Activation and Functions of Col6a1+ Fibroblasts in Colitis-Associated Cancer.  |  Chalkidi, N., et al. 2023. Int J Mol Sci. 25: PMID: 38203319
5. COL6A3 enhances the osteogenic differentiation potential of BMSCs by promoting mitophagy in the osteoporotic microenvironment.  |  Wang, K., et al. 2024. Mol Biol Rep. 51: 206. PMID: 38270688
6. Splicing Switching of Alternative Last Exons Due to a Deletion Including Canonical Polyadenylation Site in COL6A2 Gene Causes Recessive UCMD.  |  El Sherif, R., et al. 2024. Neurol Genet. 10: e200137. PMID: 38544966
7. Optimized allele-specific silencing of the dominant-negative COL6A1 G293R substitution causing collagen VI-related dystrophy.  |  Brull, A., et al. 2024. Mol Ther Nucleic Acids. 35: 102178. PMID: 38617974
8. Identification and validation of COL6A1 as a novel target for tumor electric field therapy in glioblastoma.  |  Chen, J., et al. 2024. CNS Neurosci Ther. 30: e14802. PMID: 38887185
9. A Damaging COL6A3 Variant Alters the MIR31HG-Regulated Response of Chondrocytes in Neocartilage Organoids to Hyperphysiologic Mechanical Loading.  |  Bloks, NG., et al. 2024. Adv Sci (Weinh). 11: e2400720. PMID: 39021299
10. COL6A3 Exosomes Promote Tumor Dissemination and Metastasis in Epithelial Ovarian Cancer.  |  Ho, CM., et al. 2024. Int J Mol Sci. 25: PMID: 39125689

The preferred COL6A1 antibody is COL6A1 Antibody (B-4): sc-377143.